Muscle protein anabolism in advanced cancer patients: Response to protein and amino acids support, and to physical activity

Annals of Oncology

Volumn 29, Issue , 2018, Pages ii10-ii17

  Antoun, Sami ^a   Raynard, B ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cachexia; Muscle; Physical activity; Protein anabolism; Sarcopenia

Indexed keywords

AMINO ACID; ARGININE; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; ESSENTIAL AMINO ACID; GLUCOSE TRANSPORTER 4; GLUTAMINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LEUCINE; MYOCYTE ENHANCER FACTOR 2; OMEGA 3 FATTY ACID; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; MUSCLE PROTEIN;

ADVANCED CANCER; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT LOSS; CACHEXIA; CALORIC INTAKE; CANCER FATIGUE; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERINSULINEMIA; IMAGE ANALYSIS; INSULIN RESISTANCE; KARNOFSKY PERFORMANCE STATUS; LEAN BODY WEIGHT; MUSCLE BIOPSY; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; NON SMALL CELL LUNG CANCER; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PANCREAS CANCER; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RESTING ENERGY EXPENDITURE; SARCOPENIA; SKELETAL MUSCLE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ADMINISTRATION AND DOSAGE; ANIMAL; ANIMAL EXPERIMENT; BIOSYNTHESIS; CANCER STAGING; COMPLICATION; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECT; EXERCISE; KINESIOTHERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROCEDURES; PROTEIN INTAKE;

ANIMALS; ANTINEOPLASTIC AGENTS; CACHEXIA; COMBINED MODALITY THERAPY; DIETARY PROTEINS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; EXERCISE; EXERCISE THERAPY; HUMANS; LEUCINE; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOPLASM STAGING; NEOPLASMS; PHYSICAL CONDITIONING, ANIMAL; POSTOPERATIVE COMPLICATIONS; PROTEIN BIOSYNTHESIS;

EID: 85043390488     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx809     Document Type: Article

References (68)

1. Blum D, Stene GB, Solheim TS et al. Validation of the consensusdefinition for cancer cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRCCSA). Ann Oncol 2014; 25(8): 1635-1642.
2. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12(5):489-495.
3. Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases:from sarcopenic obesity to cachexia. Clin Nutr 2014; 33(5):737-748.
4. Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9(7): 629-635.
5. Tan BH, Birdsell LA, Martin L et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15(22): 6973-6979.
6. Martin L, Birdsell L, Macdonald N et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547.
7. Kasymjanova G, Correa JA, Kreisman H et al. Prognostic value of the sixminute walk in advanced non-small cell lung cancer. J Thorac Oncol 2009; 4(5): 602-607.
8. Kilgour RD, Vigano A, Trutschnigg B et al. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 2013; 21(12):3261-3270.
9. Prado CM, Baracos VE, McCargar LJ et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13(11): 3264-3268.
10. Antoun S, Baracos VE, Birdsell L et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21(8): 1594-1598.
11. Mir O, Coriat R, Blanchet B et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7(5): e37563.
12. Massicotte MH, Borget I, Broutin S et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebocontrolled study. J Clin Endocrinol Metab 2013; 98(6): 2401-2408.
13. Huang DD, Wang SL, Zhuang CL et al. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 2015; 17(11): O256-O264.
14. Reisinger KW, van Vugt JL, Tegels JJ et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg 2015; 261(2): 345-352.
15. Prado CM, Sawyer MB, Ghosh S et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013; 98(4): 1012-1019.
16. Drummond MJ, Dreyer HC, Fry CS et al. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J Appl Physiol 2009; 106(4): 1374-1384.
17. Ham DJ, Caldow MK, Lynch GS, Koopman R. Leucine as a treatment for muscle wasting: a critical review. Clin Nutr 2014; 33(6): 937-945.
18. Lundholm K, Edström S, Ekman L et al. A comparative study of the influence of malignant tumor on host metabolism in mice and man. Cancer 1978; 42(2): 453-461.
19. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012; 31(5): 765-773.
20. van Dijk DP, van de Poll MC, Moses AG et al. Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J Cachexia Sarcopenia Muscle 2015; 6(3):212-221.
21. Engelen MP, Safar AM, Bartter T et al. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol 2015; 26(9): 1960-1966.
22. Williams JP, Phillips BE, Smith K et al. Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients. Am J Clin Nutr 2012; 96: 1064-1070.
23. Dillon EL, Volpi E, Wolfe RR et al. Amino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy. Clin Nutr 2007; 26(6): 736-743.
24. Deutz NE, Safar A, Schutzler S et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011; 30(6): 759-768.
25. Bozzetti F, Bozzetti V. Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature. Clin Nutr 2013; 32(1): 142-146.
26. May PE, Barber A, D'Olimpio JT et al. Reversal of cancer-related wasting using oral supplementation with a combination of b-hydroxy-b-methylbutyrate, arginine, and glutamine. Am J Surg 2002; 183(4): 471-479.
27. Berk L, James J, Schwartz A et al. A randomized, double-blind, placebocontrolled trial of a b-hydroxy-b-methylbutyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer 2008; 16(10): 1179-1188.
28. Choudry HA, Pan M, Karinch AM, Souba WW. Branched-chain amino acid-enriched nutritional support in surgical and cancer patients. J Nutr 2006; 136(Suppl 1): 314S-318S.
29. Yoshiji H, Noguchi R, Ikenaka Y et al. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. Mol Med Rep 2012; 5: 539-544.
30. Kawaguchi T, Shiraishi K, Ito T et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12(6): 1012-1018.
31. Chevalier S, Winter A. Do patients with advanced cancer have any potential for protein anabolism in response to amino acid therapy? Curr Opin Clin Nutr Metab Care 2014; 17(3): 213-218.
32. Jonker R, Engelen MP, Deutz NE. Role of specific dietary amino acids in clinical conditions. Br J Nutr 2012; 108 Suppl 2: S139-S148.
33. de Luis DA, Izaola O, Terroba MC et al. Effect of three different doses of arginine enhanced enteral nutrition on nutritional status and outcomes in well-nourished postsurgical cancer patients: a randomized single blinded prospective trial. Eur Rev Med Pharmacol Sci 2015; 19: 950-955.
34. Penna F, Busquets S, Pin F et al. Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachexia Sarcopenia Muscle 2011; 2(2): 95-104.
35. Lira FS1, Yamashita AS, Rosa JC et al. Hypothalamic inflammation is reversed by endurance training in anorectic-cachectic rats. Nutr Metab (Lond) 2011; 8(1): 60.
36. Puppa MJ, White JP, Velázquez KT et al. The effect of exercise on IL-6- induced cachexia in the Apc (Min/(thorn)) mouse. J Cachexia Sarcopenia Muscle 2012; 3(2): 117-137.
37. Lira FS, Yamashita AS, Rosa JC et al. Exercise training decreases adipose tissue inflammation in cachectic rats. Horm Metab Res 2012; 44(02): 91-98.
38. Gould DW, Lahart I, Carmichael AR et al. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle 2013; 4(2): 111-124.
39. Lira FS, Neto JC, Seelaender M. Exercise training as treatment in cancer cachexia. Appl Physiol Nutr Metab 2014; 39(6): 679-686.
40. Pigna E, Berardi E, Aulino P et al. Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer. Sci Rep 2016; 6(1): 26991.
41. Daneryd PL, Hafström LR, Karlberg IH. Effects of spontaneous physical exercise on experimental cancer anorexia and cachexia. Eur J Cancer 1990; 26(10): 1083-1088.
42. Jee H, Chang JE, Yang EJ. Positive prehabilitative effect of intense treadmill exercise for ameliorating cancer cachexia symptoms in a mouse model. J Cancer 2016; 7(15): 2378-2387.
43. Donatto FF, Neves RX, Rosa FO et al. Resistance exercise modulates lipid plasma profile and cytokine content in the adipose tissue of tumourbearing rats. Cytokine 2013; 61(2): 426-432.
44. Daneryd P, Hafström L, Svanberg E, Karlberg I. Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur J Cancer 1995; 31(1): 97-103.
45. al-Majid S, McCarthy DO. Resistance exercise training attenuates wasting of the extensor digitorum longus muscle in mice bearing the colon-26 adenocarcinoma. Biol Res Nurs 2001; 2(3): 155-166.
46. Hojman P, Fjelbye J, Zerahn B et al. Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. PLoS One 2014; 9(9): e109030.
47. Khamoui AV, Park BS, Kim DH et al. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia. Metab Clin Exp 2016; 65: 685-698.
48. Solheim TS, Laird BJA, Balstad TR et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017; doi: 10.1002/jcsm.12201.
49. Mustian KM, Alfano CM, Heckler C et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3(7): 961-968.
50. Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults:executive summary of a cochrane collaboration systematic review. J Cachexia Sarcopenia Muscle 2015; 6(3): 208-211.
51. Galvão DA, Taaffe DR, Spry N et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340-347.
52. Nedergaard A, Dalgas U, Primdahl H et al. Collagen fragment biomarkers as serological biomarkers of lean body mass-a biomarker pilot study from the DAHANCA25B cohort and matched controls. J Cachexia Sarcopenia Muscle 2015; 6(4): 335-342.
53. Lønbro S, Dalgas U, Primdahl H et al. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy-results from the randomized DAHANCA 25B trial. Radiother Oncol 2013; 108(2): 314-319.
54. Lønbro S, Dalgas U, Primdahl H et al. Lean body mass and muscle function in head and neck cancer patients and healthy individuals-results from the DAHANCA 25 study. Acta Oncol 2013; 52(7): 1543-1551.
55. Adamsen L, Quist M, Andersen C et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy:randomised controlled trial. Br Med J 2009; 339: b3410.
56. Courneya KS, Sellar CM, Stevinson C et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605-4612.
57. Courneya KS, Jones LW, Peddle CJ et al. Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. Oncologist 2008; 13(9): 1012-1020.
58. Litterini AJ1, Fieler VK, Cavanaugh JT, Lee JQ. Differential effects of cardiovascular and resistance exercise on functional mobility in individuals with advanced cancer: a randomized trial. Arch Phys Med Rehabil 2013; 94(12): 2329-2335.
59. van den Dungen IA, Verhagen CA, van der Graaf WT et al. Feasibility and impact of a physical exercise program in patients with advanced cancer:a pilot study. J Palliat Med 2014; 17(10): 1091-1098.
60. Chasen MR, Feldstain A, Gravelle D et al. An interprofessional palliative care oncology rehabilitation program: effects on function and predictors of program completion. Curr Oncol 2013; 20(6): 301-309.
61. Temel JS, Greer JA, Goldberg S et al. A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4(5): 595-601.
62. Oldervoll LM, Loge JH, Lydersen S et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16(11): 1649-1657.
63. Glare P, Jongs W, Zafiropoulos B. Establishing a cancer nutrition rehabilitation program (CNRP) for ambulatory patients attending an Australian cancer center. Support Care Cancer 2011; 19(4): 445-454.
64. Maddocks M, Armstrong S, Wilcock A. Exercise as a supportive therapy in incurable cancer: exploring patient preferences. Psychooncology 2011; 20(2): 173-178.
65. Pyszora A, Budzyński J,Wójcik A et al. Physiotherapy programme reduces fatigue in patients with advanced cancer receiving palliative care: randomized controlled trial. Support Care Cancer 2017; 25(9): 2899-2908.
66. Del Fabbro E, Hui D, Dalal S et al. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med 2011; 14(9):1004-1008.
67. Kapoor N, Naufahu J, Tewfik S et al. A prospective randomized controlled trial to study the impact of a nutrition-sensitive intervention on adult women with cancer cachexia undergoing palliative care in India. Integr Cancer Ther 2017; 16(1): 74-84.
68. Deutz NE, Wolfe RR. Is there a maximal anabolic response to protein intake with a meal? Clin Nutr 2013; 32(2): 309-313.